Apex Laboratories gets approval for CleVira as COVID supportive drug

City based pharma company Apex Laboratories will take the doctor's prescription route for its oral antiviral CleVira tablet that got the Central government's approval as a supporting measure for mild to moderate condition of COVID-19, a senior official said.

Apex Laboratories said it has got the approval from the Ministry of Ayush for its antiviral drug Clevira as a supporting measure for mild to moderate condition of COVID-19.

The company said this is the first of its kind approval in India through various stages of scrutiny at The Central Council for Research in Ayurvedic Sciences and Interdisciplinary Technical Review Committee.

According to the official, the company will position this as a doctor prescribed drug and not as an over-the-counter sales drug.

The company said a phase III Clinical trial was carried out in Government Medical College Omandurar Government Estate Chennai with Tamil Nadu government's approval.

The trial outcomes revealed that Clevira has shown 86 per cent recovery rate on fifty day of treatment in mild to moderate COVID-19 cases.

The official said enquiries from the medical practitioner world have started for CleVira as a medicine for COVID-19 following the approval from the Ministry of Ayush.

The company's flagship product is Zincovit which is in good demand from corporate hospitals for COVID-19. Apex Laboratories is also into dermatology, pain management, anti-infectives, anti-viral, nutraceuticals and herbal products.